Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Back to the Future: Lessons Learned From the 1918 Influenza Pandemic.

Short KR, Kedzierska K, van de Sandt CE.

Front Cell Infect Microbiol. 2018 Oct 8;8:343. doi: 10.3389/fcimb.2018.00343. eCollection 2018. Review.

2.

Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines.

Altenburg AF, van Trierum SE, de Bruin E, de Meulder D, van de Sandt CE, van der Klis FRM, Fouchier RAM, Koopmans MPG, Rimmelzwaan GF, de Vries RD.

Sci Rep. 2018 Apr 24;8(1):6474. doi: 10.1038/s41598-018-24820-2.

3.

H1N1pdm09 Influenza Virus and Its Descendants Lack Extra-epitopic Amino Acid Residues Associated With Reduced Recognition by M158-66-Specific CD8+ T Cells.

van de Sandt CE, Sagong KA, Pronk MR, Bestebroer TM, Spronken MI, Koopmans MPG, Fouchier RAM, Rimmelzwaan GF.

J Infect Dis. 2018 Jul 13;218(4):581-585. doi: 10.1093/infdis/jiy218.

4.

Variation at Extra-epitopic Amino Acid Residues Influences Suppression of Influenza Virus Replication by M158-66 Epitope-Specific CD8+ T Lymphocytes.

van de Sandt CE, Pronk MR, van Baalen CA, Fouchier RAM, Rimmelzwaan GF.

J Virol. 2018 May 14;92(11). pii: e00232-18. doi: 10.1128/JVI.00232-18. Print 2018 Jun 1.

5.

Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo.

Altenburg AF, van de Sandt CE, Li BWS, MacLoughlin RJ, Fouchier RAM, van Amerongen G, Volz A, Hendriks RW, de Swart RL, Sutter G, Rimmelzwaan GF, de Vries RD.

Sci Rep. 2017 Aug 17;7(1):8580. doi: 10.1038/s41598-017-08719-y.

6.

A compensatory mutagenesis study of a conserved hairpin in the M gene segment of influenza A virus shows its role in virus replication.

Spronken MI, van de Sandt CE, de Jongh EP, Vuong O, van der Vliet S, Bestebroer TM, Olsthoorn RCL, Rimmelzwaan GF, Fouchier RAM, Gultyaev AP.

RNA Biol. 2017 Nov 2;14(11):1606-1616. doi: 10.1080/15476286.2017.1338243. Epub 2017 Jul 21.

7.

Human CD8+ T Cells Damage Noninfected Epithelial Cells during Influenza Virus Infection In Vitro.

van de Sandt CE, Bárcena M, Koster AJ, Kasper J, Kirkpatrick CJ, Scott DP, de Vries RD, Herold S, Rimmelzwaan GF, Kuiken T, Short KR.

Am J Respir Cell Mol Biol. 2017 Nov;57(5):536-546. doi: 10.1165/rcmb.2016-0377OC.

PMID:
28613916
8.

Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.

Altenburg AF, van de Sandt CE, van Trierum SE, De Gruyter HLM, van Run PRWA, Fouchier RAM, Roose K, Saelens X, Volz A, Sutter G, de Vries RD, Rimmelzwaan GF.

J Virol. 2016 Oct 28;90(22):10209-10219. doi: 10.1128/JVI.01633-16. Print 2016 Nov 15.

9.

Differential Recognition of Influenza A Viruses by M158-66 Epitope-Specific CD8+ T Cells Is Determined by Extraepitopic Amino Acid Residues.

van de Sandt CE, Kreijtz JH, Geelhoed-Mieras MM, Nieuwkoop NJ, Spronken MI, van de Vijver DA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

J Virol. 2015 Nov 4;90(2):1009-22. doi: 10.1128/JVI.02439-15. Print 2016 Jan 15.

10.

Influenza B viruses: not to be discounted.

van de Sandt CE, Bodewes R, Rimmelzwaan GF, de Vries RD.

Future Microbiol. 2015;10(9):1447-65. doi: 10.2217/fmb.15.65. Epub 2015 Sep 11. Review.

PMID:
26357957
11.

Influenza B virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineage.

van de Sandt CE, Dou Y, Vogelzang-van Trierum SE, Westgeest KB, Pronk MR, Osterhaus AD, Fouchier RA, Rimmelzwaan GF, Hillaire ML.

J Gen Virol. 2015 Aug;96(8):2061-73. doi: 10.1099/vir.0.000156. Epub 2015 Apr 21.

12.

Immunodominant responses to the influenza virus M158-66 epitope: Stealth or protection?

van de Sandt CE, Rimmelzwaan GF.

Proc Natl Acad Sci U S A. 2015 May 12;112(19):E2417. doi: 10.1073/pnas.1503245112. Epub 2015 Apr 6. No abstract available.

13.

Human Influenza A Virus-Specific CD8+ T-Cell Response Is Long-lived.

van de Sandt CE, Hillaire ML, Geelhoed-Mieras MM, Osterhaus AD, Fouchier RA, Rimmelzwaan GF.

J Infect Dis. 2015 Jul 1;212(1):81-5. doi: 10.1093/infdis/jiv018. Epub 2015 Jan 12.

14.

An autotransporter display platform for the development of multivalent recombinant bacterial vector vaccines.

Jong WS, Daleke-Schermerhorn MH, Vikström D, Ten Hagen-Jongman CM, de Punder K, van der Wel NN, van de Sandt CE, Rimmelzwaan GF, Follmann F, Agger EM, Andersen P, de Gier JW, Luirink J.

Microb Cell Fact. 2014 Nov 25;13:162. doi: 10.1186/s12934-014-0162-8.

15.

Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.

van de Sandt CE, Kreijtz JH, Geelhoed-Mieras MM, Vogelzang-van Trierum SE, Nieuwkoop NJ, van de Vijver DA, Fouchier RA, Osterhaus AD, Morein B, Rimmelzwaan GF.

Vaccine. 2014 Sep 29;32(43):5614-23. doi: 10.1016/j.vaccine.2014.08.003. Epub 2014 Aug 17.

PMID:
25140929
16.

Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virus.

van de Sandt CE, Kreijtz JH, de Mutsert G, Geelhoed-Mieras MM, Hillaire ML, Vogelzang-van Trierum SE, Osterhaus AD, Fouchier RA, Rimmelzwaan GF.

J Virol. 2014 Feb;88(3):1684-93. doi: 10.1128/JVI.02843-13. Epub 2013 Nov 20.

17.

Evasion of influenza A viruses from innate and adaptive immune responses.

van de Sandt CE, Kreijtz JH, Rimmelzwaan GF.

Viruses. 2012 Sep;4(9):1438-76. doi: 10.3390/v4091438. Epub 2012 Sep 3. Review.

Supplemental Content

Loading ...
Support Center